Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 33-37
- https://doi.org/10.3816/clc.2011.n.004
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium TrialJournal of Thoracic Oncology, 2006
- Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell linesInternational Journal of Cancer, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced ApoptosisThe Annals of Thoracic Surgery, 2004
- Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer CellsOnline Journal of Public Health Informatics, 2003
- Chemosensitization of Pancreatic Cancer by Inhibition of the 26S ProteasomeJournal of Surgical Research, 2001
- The ubiquitin‐proteasome pathway and proteasome inhibitorsMedicinal Research Reviews, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000